Home > Insider Trading > Filing (0000899243-17-023140)

Filing Details

Accession Number:: 0000899243-17-023140
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-10-02 16:42:16
Reporting Period:: 2017-10-02

Accepted Time:: 2017-10-02 16:42:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1654151	Deciphera Pharmaceuticals Inc.	DCPH	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1625653	New Leaf Ventures Iii, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625656	New Leaf Venture Associates Iii, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625657	New Leaf Venture Management Iii, L.l.c.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625693	New Leaf Bpo Associates I, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No
1625696	New Leaf Biopharma Opportunities I, L.p.	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-10-02	839,110	$0.00	839,110	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-10-02	1,118,722	$0.00	1,957,832	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-10-02	279,703	$0.00	279,703	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-10-02	1,118,722	$0.00	1,398,425	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-10-02	372,883	$0.00	1,771,308	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-10-02	375,000	$17.00	2,146,308	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred Stock	Disposition	2017-10-02	148,515	$0.00	839,110	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2017-10-02	198,004	$0.00	1,118,722	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2017-10-02	49,505	$0.00	279,703	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2017-10-02	198,004	$0.00	1,118,722	$0.00
Common Stock	Series C Preferred Stock	Disposition	2017-10-02	65,997	$0.00	372,883	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer.
The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.